Skip to content

Category: News

Assessing the Impact of the Research to Accelerate Cures and Equity (RACE) Act

On February 15th, Friends of Cancer Research hosted a virtual public meeting, “Enhancing Diversity in Clinical Trials: Implementation of Diversity Plans,” emphasizing the importance of ensuring diverse representation in clinical trials to promote health equity, minimize biases, and foster holistic approaches in scientific research.

Watch Now: Unlocking Complex Cell-Based Gene Therapies

On February 15th, Friends of Cancer Research hosted a virtual public meeting, “Enhancing Diversity in Clinical Trials: Implementation of Diversity Plans,” emphasizing the importance of ensuring diverse representation in clinical trials to promote health equity, minimize biases, and foster holistic approaches in scientific research.

Watch Now: Enhancing Diversity in Clinical Trials: Implementation of Diversity Plans

On February 15th, Friends of Cancer Research hosted a virtual public meeting, “Enhancing Diversity in Clinical Trials: Implementation of Diversity Plans,” emphasizing the importance of ensuring diverse representation in clinical trials to promote health equity, minimize biases, and foster holistic approaches in scientific research.

rw-Response Pilot Moves Forward with Meeting During ASCO

During the American Society of Clinical Oncology (ASCO) Annual Meeting in June, Friends of Cancer Research (Friends) convened rw-Response Pilot participants to discuss initial findings. This pilot expands on Friends’ previous real-world evidence (RWE) work focused on answering the question: “What real-world endpoints can be evaluated and compared across multiple data sources using a common…

Optimizing the Use of Accelerated Approval

The first white paper, “Modernizing Expedited Development Programs” focused on expediting the development of drugs at the pre-clinical and clinical stages. On Day 2 of the 2020 Friends of Cancer Research (Friends) Annual Meeting, panelists will examine the second whitepaper, “Optimizing the Use of Accelerated Approval.” This white paper examines opportunities to optimize accelerated approval…

Modernizing Expedited Development Programs

Each year, the Friends of Cancer Research (Friends) Annual Meeting addresses critical issues in the development of new oncology drugs and features experts proposing unique approaches toward current challenges in drug development. On Day 1 of the 2020 Friends Annual Meeting, panelists will discuss FDA’s expedited development programs and discuss proposals outlined in the white…

An International Framework for Real-World Evidence – Day 1: RWE Pilot Project Results

September 21st was the first day of the Friends of Cancer Research (Friends) virtual meeting on real-world evidence (RWE). Day 1 covered findings from the RWE Pilot 2.0 Project, exploring the outcomes of patients with advanced non-small cell lung cancer (aNSCLC) treated with immunotherapy versus chemotherapy, as well as related RWE projects from partner institutions…

A Culmination of the Real-World Evidence Pilot Projects

This is the final post in the Real-World Evidence (RWE) blog series where we will discuss the Friends of Cancer Research (Friends) whitepaper titled: “Recommendations for Use of Real-world Evidence in Oncology: Lessons Learned from the Friends of Cancer Research Real-world Evidence Framework. ”   The whitepaper, informed by the pilot projects we reviewed in…

Using RWE Pilot 2.0 to Confirm Internal Consistency in Clinical Trials

This is the fourth installment in our Real-World Evidence (RWE) blog series where we highlight key findings and implications from the RWE pilot projects. You may view previous posts here, here, and here. In this post, we will review the Internal Consistency project, which investigated use of the RWE framework to select a clinical trial…

Expanded Applications to Validate the Real-World Evidence Framework

In our previous blog posts we discussed Pilot 1.0 and Pilot 2.0 of the Real-World Evidence (RWE) Project. The goal of the RWE pilots is to create better characterization for the role real-world endpoints could play in evaluating drug effectiveness. In this blog, we will review two collaborations that formed between Friends of Cancer Research…